Alvotech Reports Efficacy and PK Results for AVT02
Icelandic company Alvotech said clinical trials for its adalimumab candidate have demonstrated equivalence to reference product Humira.
Alvotech, of Reykjavik, Iceland, said its high-concentration adalimumab biosimilar (AVT02) has performed successfully in separate clinical trials for efficacy and pharmacokinetic (PK) similarity.
The company added that both studies demonstrated no clinically meaningful differences for safety, tolerability, and immunogenicity between AVT02 and the reference product (Humira).
Alvotech aims to eventually market AVT02 in the United States, Europe, and selected Southeast Asia markets.
A Partnership to Commercialize
In a March 2020 statement, Alvotech said it had partnered with DKSH, of Zurich, Switzerland, to commercialize AVT02. The biosimilar candidate has yet to be certified as a biosimilar or approved for marketing in any country.
AbbVie’s Humira is indicated for multiple autoimmune diseases, including rheumatoid arthritis, ankylosing spondlytis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn disease. Humira had worldwide sales of $18.4 billion in 2017.
AVT02 is being developed with a 100 mg/mL dose form that Alvotech believes will differentiate its product from “most biosimilar competitors, while matching the newest dosage forms of the reference product.”
The drug falls within the family of anti—tumor necrosis factor (TNF) agents. It contains a monoclonal antibody and blocks the activity of TNF, which normally helps the body control infection but leads to serious inflammation when produced in excess amounts.
The total market value for TNF-inhibitors in 2018 was over $40 billion and is expected to expand at the annual rate of 16.5% through 2026, Alvotech said.
An "Exciting Time" for Alvotech
“This is an exciting time for Alvotech as we advance the first biosimilar program another step closer to patients around the world. Our goal is to provide patients and healthcare providers with a cost-effective, accessible alternative to therapies which are currently available,” said Joseph E. McClellan, chief scientific officer at Alvotech.
In its statement, Alvotech explained that a phase 1 clinical study to compare the PK between AVT02 and Humira following a single 40 mg subcutaneous injection in health adult volunteers has met its primary objective. All primary PK end points were within equivalence margins, demonstrating PK similarity of AVT02 to the reference product.
The phase 3 comparative, confirmatory study for AVT02 also met its primary objective by demonstrating equivalent efficacy. The study is evaluating efficacy, safety, and immunogenicity of AVT02 compared with Humira in patients with moderate-to-severe chronic plaque psoriasis.
Reference
Alvotech announces positive top-line results for two comparative studies for AVT02, a proposed biosimilar to Humira (adalimumab). News release. Alvotech. May 12, 2020. Accessed May 14, 2020. www.alvotech.com/newsroom/alvotech-announces-positive-top-line-results-for-two-comparative-studies-for-avt02-a-proposed-biosimilar-to-humira-adalimumab
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.
